Victory Capital Management
VYNE icon

Victory Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Victory Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-316
Closed -$36K – 2774
2020
Q4 		$36K Sell
316
-2
-0.6% -$251 ﹤0.01% 2476
2020
Q3 		$38K Sell
318
-32
-9% -$3.73K ﹤0.01% 2399
2020
Q2 		$44K Buy
350
+221
+171% +$29.9K ﹤0.01% 2405
2020
Q1 		$24K Buy
+129
New +$40.5K ﹤0.01% 3041
2019
Q4 		– Sell
-23
Closed -$7K – 3282
2019
Q3 		$7K Buy
+23
New +$7.42K ﹤0.01% 3373

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Victory Capital Management's VYNE Position: Q1 2021 in Review

Victory Capital Management sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 316 shares — an estimated $36K sold.

Victory Capital Management first reported a position in VYNE in Q3 2019 and held it in 5 quarters. The position peaked at $44K in Q2 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • Victory Capital Management reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Victory Capital Management sold 316 VYNE Therapeutics shares in Q1 2021, an estimated $36K.
  • Victory Capital Management first reported a position in VYNE Therapeutics in Q3 2019 and held it in 5 quarters.
  • Victory Capital Management's VYNE Therapeutics position peaked at $44K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Victory Capital Management's 13F filing for Q1 2021, filed 4 May 2021.